Harmony Biosciences (HRMY) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
18 May, 2026Opening remarks and agenda
The meeting was called to order at 1:00 P.M. Eastern Time, with the agenda posted on the virtual meeting website and notice provided to all stockholders of record as of March 17, 2026.
Proof of notice, proxy materials, and annual report distribution was confirmed, and a quorum was established, allowing the meeting to proceed.
Company officers, board members, and representatives from the independent accounting firm were present, with rules of conduct posted for orderly proceedings.
Board and executive committee updates
Four Class 3 directors—Gino Germano, Troy Ignelzi, Ron Philip, and Andreas Wicki—were nominated to serve until the 2029 annual meeting.
The board unanimously recommended the election of these nominees.
Shareholder proposals
Three proposals were presented: election of directors, ratification of Deloitte & Touche LLP as independent auditor for 2026, and a non-binding advisory vote on executive compensation.
The board unanimously recommended approval of all proposals.
Latest events from Harmony Biosciences
- Pipeline advances and new formulations target CNS and epilepsy markets, driven by strong sales.HRMY
Piper Sandler Virtual CNS Symposium - Q2 2026 revenue up 30% to $261.3M, with strong WAKIX growth and pipeline advancement.HRMY
Q2 2026 - Four-pillar strategy drives WAKIX growth, orexin pipeline, and targeted business development.HRMY
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Q1 2026 revenue up 17% to $215.4M; full-year guidance reaffirmed at $1.0–$1.04B.HRMY
Q1 2026 - WAKIX momentum, pipeline innovation, and strategic BD drive growth and CNS leadership.HRMY
25th Annual Needham Virtual Healthcare Conference - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.HRMY
Proxy filing - 2025 revenue up 22% year-over-year; 2026 WAKIX guidance set at $1.0–$1.04B.HRMY
Q4 2025 - Q1 2025 revenue up 20% to $184.7M, net income $45.6M, and 2025 guidance reaffirmed.HRMY
Q1 2025 - 2024 revenue up 23% to $714.7M, with strong WAKIX sales and robust 2025 growth outlook.HRMY
Q4 2024